1Shaw J E,Sicree RA,Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030[J].Diabetes Research and Clinical Practice,2010,(01):4-14.
2Brubaker PL,Drucker DJ. Minireview:Glucagon-like peptides regulate cellproliferation and apoptosis in the pancreas,gut,and central nervous system[J].Endocrinology,2004,(06):2653-2659.
3Hui H,Nourparvar A,Zhao X. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A-and a phosphatidylinositol 3-kinase-dependent pathway[J].Endocrinology,2003,(04):1444-1455.
4Stoffers DA,Kieffer TJ,Hussain MA. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas[J].Diabetes,2000,(05):741-748.doi:10.2337/diabetes.49.5.741.
5Doyle ME,Theodorakis MJ,Holloway HW. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity[J].Regulatory Peptides,2003,(2-3):153-158.
6Neidigh JW,Fesinmeyer RM,Pricket KS. Exendin-4 and glucagon-like-peptide-1:NMR structural comparisons in the solution and micelle-associated states[J].Biochemistry,2001,(44):13188-13200.doi:10.1021/bi010902s.
7Harder H,Nielsen L,Tu DT. The effect of Liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes[J].Diabetes Care,2004,(08):1915-1921.doi:10.2337/diacare.27.8.1915.
8Garber A,Henry R,Ratner R. Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3 Mono):a randomised,52-week,phase III,double-blind,paral el-treatment trial[J].The Lancet,2009,(9662):473-481.doi:10.1016/S0140-6736(08)61246-5.
9Buse JB,Rosenstock J,Sesti G. Liraglutide once a day versus Exenatide twice a day for type 2 diabetes:a 26-week randomised,parallel-group,multinational,open-label trial(LEAD-6)[J].The Lancet,2009,(9683):39-47.doi:10.1016/S0140-6736(09)60659-0.
10Baggio LL,Huang Q,Brown TJ. A recombinant human glucagon-like peptide(GLP)-1-albumin protein(albugon)mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety,gastrointestinal motility,and glucose homeostasis[J].Diabetes,2004,(09):2492-2500.doi:10.2337/diabetes.53.9.2492.
